{"id":"W4387903322","doi":"10.1038/s41467-023-42400-5","title":"Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Universität Heidelberg; Bristol-Myers Squibb Canada; Deutsches Krebsforschungszentrum","keywords":"Ipilimumab; Nivolumab; Refractory (planetary science); Medicine; Oncology; Primary (astronomy); Cancer; Internal medicine; Clinical trial; Immunotherapy; Biology; Physics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001511657,0.00009509851,0.0002745707,0.0001716421,0.0001001502,0.000005547754,0.000170953,0.0001378015,0.00004778729],"category_scores_gemma":[0.0001231791,0.00007381743,0.00005546453,0.0005300311,0.00009456163,0.00004320774,0.0002127916,0.0004798828,0.000002528981],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002504861,"about_ca_system_score_gemma":0.0003237849,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002426055,"about_ca_topic_score_gemma":0.005601803,"domain_scores_codex":[0.9992563,0.00005940947,0.0002557755,0.0001581286,0.0001478573,0.0001225199],"domain_scores_gemma":[0.9986005,0.0002665283,0.00009610347,0.0008920952,0.00008437721,0.00006044234],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.05073212,0.02435284,0.01078186,0.0004024012,0.0006107936,0.00003821797,0.00466165,0.000003269217,0.001860203,0.003957811,0.1142554,0.7883434],"study_design_scores_gemma":[0.1790797,0.005584209,0.06085743,0.0009697559,0.000390393,0.000008519709,0.00022285,0.0002968964,0.0004448833,0.0001084067,0.751801,0.0002360192],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9444567,0.04033989,2.832967e-7,0.01242191,0.0002649967,0.001018177,0.0001220254,0.00005569944,0.001320325],"genre_scores_gemma":[0.9562372,0.04220526,0.0002614465,0.0001887649,0.00005784289,0.0004387657,0.0002052187,0.00001287361,0.000392659],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7881075,"threshold_uncertainty_score":0.3125938,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06261548164402625,"score_gpt":0.4218822484764692,"score_spread":0.359266766832443,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}